As­cendis Phar­ma's hy­poparathy­roidism drug scores Eu­ro­pean ap­proval af­ter re­fil­ing in the US

As­cendis Phar­ma’s Yorvipath was ap­proved in Eu­rope on Mon­day, days af­ter the com­pa­ny re­filed its ap­pli­ca­tion for the hy­poparathy­roidism hope­ful in the US.

Yorvipath, al­so …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER